On November 20, WUXI BIO fell 5.52% in Regular Trading, trading at HK$40.78, with turnover of HK$303 million.
The clearest catalyst in publicly available information is BlackRock’s earlier disclosure that its stake in WUXI BIO was reduced to 5.76%, which has remained a direct overhang on the shares.
Background context shows earlier positives, including the Fresenius collaboration covering up to 37 biosimilar candidates over the next 10 years and expectations for a possible guidance upgrade, had already been repeatedly traded, leaving the stock more sensitive to position-change disclosures. The Life Sciences Tools & Services sector was also weak, with WUXI APPTEC falling 3.5%, GENSCRIPT B-1K falling 8.42%, INSILICO falling 6.22%, WUXI XDC falling 6.32%, and XTALPI falling 4.3%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments